UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer

Inclusion Criteria: * Histologic or cytological diagnosis of NSCLC who failed previous platinum-based and taxanes chemotherapy. * No prior radiotherapy on measurable lesion(s). * Performance status of 0 to 3 on the Zubrod scale. (Reference 1) * Clinically measurable disease, defined as bidimensionally measurable lesions with clearly defined margins on x-ray, scan, or physical examination. Lesions serving as measurable disease must be at least 1 cm by 1 cm, as defined by CT scan, MRI, or chest x-ray. * Informed consent from patient. * Males or females 18 years of age or older. * If female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (intrauterine contraceptive device \[IUD\], birth control pills, or barrier device) during and for three months after trial. Exclusion Criteria: * Active infection (at the discretion of the investigator). * Inadequate liver function (total bilirubin \>1.5 times above normal range); alanine transaminase (ALT) and aspartate transaminase (AST) greater than 5 times normal. * Inadequate renal function (creatinine \>2.0 mg/dL). * Breast feeding. * Second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin) * Concomitant myelosuppressive radiotherapy, chemotherapy, hormonal therapy, or immunotherapy will not be allowed except as for palliative radiation to non-measurable lesion.